2026-10-30 14:57:00 UTC#546518duplicateconfirmednews
AstraZeneca Plc stock news
AstraZeneca Plc stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-30 14:28:22 UTC#546348updateconfirmednews
AstraZeneca CFO Sarin discusses Q3 earnings beat, AI integration, and strategic dealmaking approach
2026-10-30 14:21:00 UTC#546296duplicateconfirmedanalysis
AstraZeneca outlines $1.5B annual cost-savings plan to support 2030 revenue targets
2026-10-30 10:17:44 UTC#544582newconfirmednews
FTSE 100 on track for monthly gains; AstraZeneca shares rise following earnings report
2026-10-30 09:05:15 UTC#544159duplicateconfirmednews
AstraZeneca reports 23% Q3 profit jump to $3.12B and announces $1.5B annual cost-savings program
yahooimportance 0.30trust 0.70AstraZeneca plc +0.40Pascal Soriot +0.20Reshaping for Sustainable Growth +0.20
2026-10-30 08:57:23 UTC#544060duplicateconfirmednews
AstraZeneca Q3 profit beats analyst estimates driven by oncology drug sales
2026-10-30 08:45:54 UTC#544000duplicateconfirmednews
AstraZeneca Q3 Non-GAAP EPS $2.79 and Revenue $16.21B Beat Estimates, FY2026 Outlook Reaffirmed
2026-10-30 08:36:56 UTC#543927duplicateconfirmednews
AstraZeneca Q3 adjusted EPS $2.79 beats $2.60 estimate, revenue $16.21B exceeds $16.04B forecast
2026-10-30 07:46:00 UTC#543652updateconfirmedanalysis
J.P. Morgan expects AstraZeneca shares to outperform by 2-3% following Q3 earnings beat
2026-10-30 07:40:00 UTC#543613duplicateconfirmednews
AstraZeneca Q3 net profit rises to $3.12B on strong oncology sales, beating analyst estimates
2026-10-30 07:38:00 UTC#543618duplicateconfirmednews
AstraZeneca Q3 net profit rises to $3.12B on oncology drug sales
2026-10-30 07:07:58 UTC#543410duplicateconfirmednews
AstraZeneca Q3 2026: Core EPS $2.79 vs $2.62 est, Revenue $16.21B vs $15.98B est, Guidance Reconfirmed
2026-10-30 07:07:30 UTC#543461updateconfirmednews
AstraZeneca initiates cost-savings program to boost R&D pipeline investment following Q3 sales beat
2026-10-30 07:03:08 UTC#543414duplicateconfirmednews
AstraZeneca 9M revenue up 7% at CER, Core EPS rises 14%; FY guidance reaffirmed
quartrimportance 0.40trust 0.70AstraZeneca PLC +0.40Summit Therapeutics Inc. +0.30Farxiga -0.20+1 entities
2026-10-30 07:03:08 UTC#543381newconfirmednews
AstraZeneca Q3 Core EPS $2.79 vs $2.62 Estimate
2026-10-29 15:31:00 UTC#538717newconfirmednews
Global HER2 targeted therapies market projected to reach $11.75 billion in 2026, ResearchAndMarkets reports
yahooimportance 0.30trust 0.50Pfizer Inc. +0.20Roche Holding AG +0.20AstraZeneca PLC +0.20+2 entities
2026-10-28 07:34:06 UTC#526762newconfirmednews
AstraZeneca PLC Q3 2026 earnings preview: analysts expect $2.60 EPS and $16.047B revenue
2026-10-27 18:41:59 UTC#523457newconfirmedpress release
Breast Cancer Canada and AstraZeneca Canada announce $200,000 in matched breast cancer survivorship research funding
financial postimportance 0.30trust 0.80AstraZeneca PLC +0.20Breast Cancer Canada +0.20European Society for Medical Oncology 0
2026-10-27 08:00:00 UTC#519429updateconfirmednews
AstraZeneca reports positive Phase III data for ImEdelltra+Imfinzi and Tagrisso combos; discloses $75M payment to Daiichi
tradingviewimportance 0.50trust 0.70AstraZeneca PLC +0.50Amgen Inc. +0.30Daiichi Sankyo Co., Ltd. -0.30+2 entities
2026-10-27 07:49:00 UTC#519388duplicateconfirmednews
AstraZeneca and Daiichi Sankyo receive EU approval for Enhertu in early-stage breast cancer
dow_jonesimportance 0.40trust 0.90AstraZeneca PLC +0.50Daiichi Sankyo Company, Limited +0.50Enhertu +0.60+2 entities